Try a new search

Format these results:

Searched for:

person:Anthony Aizer (aizera01) or alviac01 or axell01 or crb253 or bangas01 or babaea02 or barret02 or bergej03 or cerrom01 or chinil01 or cronsb01 or delmam01 or jad292 or feitf01 or fishee01 or fishmg01 or garshm01 or gideac01 or halped02 or heffrs01 or hochmj03 or holmed01 or jmh284 or jankel01 or aljilh01 or katzs12 or kime09 or longc08 or massed03 or moorek09 or morleg01 or newmaj05 or parkd03 or razzol01 or reyena01 or reynoh01 or saraot01 or saricm01 or bds228 or sherrm02 or ns1222 or thompc12 or vainra01 or willim33 or yuride01

active:yes

exclude-minors:true

Total Results:

3874


Cardiometabolic risk factor burden associates with an immature platelet profile

Hamo, Carine E; Muller, Matthew; Rosenfeld, Emily; Xia, Yuhe; Akinlonu, Adedoyin; Luttrell-Williams, Elliot; Barrett, Tessa J; Berger, Jeffrey S
Cardiometabolic risk factors, obesity, diabetes and hyperlipidemia contribute to cardiovascular disease (CVD). While platelets are involved in CVD pathogenesis, the relationship between risk factor burden on platelet indices and the platelet transcriptome remains uncertain. Blood was collected from CVD-free adults, measuring platelet count, mean platelet volume (MPV), immature platelet fraction (IPF), and absolute immature platelet fraction (AIPF) by hemogram. Platelets were isolated and analyzed via RNA sequencing. Participants were stratified by number of cardiometabolic risk factors (diabetes, obesity, hyperlipidemia). We calculated median (IQR) values of platelet indices and p-for-trend via linear regression across risk factor burden. To evaluate the association between risk factor burden and platelet transcripts, we performed multivariable linear regression adjusting for age, sex, and race/ethnicity. Among 141 participants, (50.5 ± 14.8 years, 42% male, 26% Black) risk factor burden was associated with increasing platelet size, IPF, and AIPF but not platelet count. Platelet RNA sequencing identified 100 differentially expressed transcripts (p < .01; 66 upregulated, 34 downregulated). Gene ontology enrichment analysis demonstrated upregulated pathways of secondary metabolic processes (NES = 1.96, p < .01), and hematopoietic stem cell proliferation (NES = 1.95, p < .01). Greater cardiometabolic risk factor burden is associated with increased platelet size and immaturity and suggesting novel platelet-mediated mechanisms linking risk factor burden with CVD.
PMID: 39882733
ISSN: 1369-1635
CID: 5781122

Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population

Mathew, Roy O; Khan, Sadiya S; Tuttle, Katherine R; Ho, Jennifer E; Abramov, Dmitry; Bangalore, Sripal; Sidhu, Mandeep S; Ndumele, Chiadi E; Powell-Wiley, Tiffany M; Neeland, Ian J; Coresh, Josef; Elkind, Mitchell S V; Rangaswami, Janani
The Predicting Risk of Cardiovascular EVENTS (PREVENT) equations, created and endorsed by the American Heart Association, provide cardiovascular risk estimates for the general population, but have not yet been tested in multiethnic populations. In the present study, in a large nationwide multiethnic sample of US veterans, the utility of PREVENT to predict the risk of total cardiovascular disease (CVD: fatal and nonfatal myocardial infarction, stroke or heart failure; PREVENT-CVD), atherosclerotic cardiovascular disease (ASCVD: fatal and nonfatal myocardial infarction or stroke; PREVENT ASCVD) and heart failure was evaluated. We assessed the discrimination and calibration performance of ASCVD prediction with PREVENT ASCVD compared with a previous risk-prediction score, pooled cohort equations (PCEs). Among 2,500,291 veterans aged 30-79 years (93.9% men and 6.1% women), 407,342 total CVD events occurred over a median (interquartile range (IQR)) follow-up of 5.8 (IQR = 3.1-8.3) years. The Concordance index (C-index) (95% confidence interval (CI)) for PREVENT-CVD was 0.65 (95% CI = 0.65-0.65) in the overall sample and was similar across different race and ethnic groups (Asian, Native Hawaiian or Pacific Islander, 0.70 (95% CI = 0.69-0.71); Hispanic, 0.70 (95% CI = 0.69-0.70); non-Hispanic Black. 0.68 (95% CI = 0.68-0.69) and non-Hispanic White, 0.65 (95% CI = 0.64-0.65)). C-indices were similar between PREVENT ASCVD and PCEs and ranged from 0.61 to 0.63. Calibration slopes for PREVENT-CVD and -ASCVD in the overall sample were 1.09 (s.e. = 0.04) and 1.15 (s.e. = 0.04), respectively. In contrast, PCEs demonstrated overprediction for ASCVD with a calibration slope of 0.51 (s.e. = 0.06). Calibration slopes for PREVENT and PCEs were similar across race and ethnic groups. Among US veterans, the PREVENT equations accurately estimated CVD and ASCVD risk with some variability across race and ethnicity groups and outperformed PCEs for ASCVD risk prediction.
PMID: 40615687
ISSN: 1546-170x
CID: 5888632

Quality improvement of a community-engaged authorship system: lessons learned from the RECOVER initiative

Esquenazi-Karonika, Shari; Mathews, Patenne D; Wood, Marion J; Mudumbi, Praveen M; Linton, Janelle; Briscoe, Jasmine; Seibert, Elle; Coombs, K; Laynor, Gregory; Katz, Stuart D; Chung, Alicia
BACKGROUND:Inclusion of patients, caregivers, and community members in scientific research should be essential for patient-centered care. Patients’ lived experiences can propose new areas of focus that may not have previously been considered, ensure that potentially sensitive topics are addressed thoughtfully, contribute to the interpretation of findings, and identify future directions of research. Further, their inclusion in the drafting of manuscripts can ensure that research findings are translatable to real-world practice. To achieve this goal, the Researching COVID to Enhance Recovery (RECOVER) consortium developed a Representative Authorship system for development of scientific manuscripts that report RECOVER data. This paper describes a Quality Improvement (QI) project that was conducted to identify system strengths and improvement opportunities. METHODS:An online QI survey was distributed to RECOVER’s Representative Authors about a year into the implementation of the Representative Authorship System. The survey focused on several key aspects, including the clarity regarding the authorship process, training opportunities, the matching process, communication within writing groups, and the perceived impact of the representative engagement on the quality and applicability of research. The survey also explored participants’ satisfaction with compensation, support, and involvement in the system, as well as areas for improvement. RESULTS:The survey was sent to 49 representative authors with 17 respondents (35%). Most respondents reported positive experiences, highlighting the effective matching to manuscripts based on their expertise and the perceived positive impact of their involvement on research outcomes. Additionally, participants felt that including diverse voices enhanced the relevance of research for clinical practice. Several areas for improvement were identified, including communication challenges within writing groups, the utility of manuscript orientation calls, and the fairness of compensation. Respondents also indicated a need for more training opportunities and logistical support. CONCLUSIONS:RECOVER’s Representative Authorship system is effective in fostering collaboration and improving the inclusivity of scientific research. The survey findings indicate that there are logistical changes around communication, training, and compensation that could enhance the experience for all collaborators. Based on these findings, we plan to implement changes to improve awareness, understanding, and collaboration. Additional work is needed to solicit feedback from investigators and administrative staff to obtain a more holistic understanding of the system. SUPPLEMENTARY INFORMATION:The online version contains supplementary material available at 10.1186/s12913-025-12914-3.
PMCID:12225380
PMID: 40611083
ISSN: 1472-6963
CID: 5888422

Left atrial wall thickness correlates with pulmonary vein reconnection following atrial fibrillation ablation

Kushnir, Alexander; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Aizer, Anthony; Park, David; Bernstein, Scott; Spinelli, Michael A; Garber, Leonid; Yang, Felix; Rosinski, Elizabeth; Chinitz, Larry A
BACKGROUND:Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF) and PV reconnection is a common cause of recurrent AF. The relationship between PV ostial wall thickness (WT) and durable PV isolation is a matter of ongoing investigation. Additionally, the relationship between catheter impedance and WT is not well understood. We studied the relationship between PV ostial WT, ablation lesion metrics, and PV reconnection. METHODS:16 patients were identified who underwent an initial and redo AF ablation procedure and had a cardiac CTA analyzed using ADAS-3D imaging software performed prior to the initial ablation. Ablation lesion metrics from the initial ablation procedure were collected from the electroanatomic mapping software. Reconnected and isolated PV were identified based on electroanatomic mapping data collected at the redo AF ablation procedure. Patients with reconnected PV exhibited thicker left atrial walls (1.4 mm vs 1.2 mm, P < 0.05) and reconnected veins exhibited thicker ostial walls (1.7 mm, vs 1.5 mm, P < 0.05). LA volume, number of ablation lesions, and ablation lesion time were not significantly different between reconnected and isolated PV. Impedance drop during ablation was greater in patients with reconnected PV compared to patients with isolated PV (- 9.0 Ω vs - 6.6 Ω, P < 0.05). There was no correlation between PV ostial WT and ablation lesion impedance drop. CONCLUSION/CONCLUSIONS:PV reconnection was associated with thicker LA and PV ostial WT. Future studies will examine whether targeting thicker PV ostial tissue with more aggressive lesion metrics or different ablation technology can improve PV isolation and ablationoutcomes.
PMID: 40542289
ISSN: 1572-8595
CID: 5871412

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Saberi, Sara; Abraham, Theodore P; Choudhury, Lubna; Barriales-Villa, Roberto; Elliott, Perry M; Nassif, Michael E; Oreziak, Artur; Owens, Anjali T; Tower-Rader, Albree; Rader, Florian; Garcia-Pavia, Pablo; Olivotto, Iacopo; Coats, Caroline J; Fifer, Michael A; Sherrid, Mark V; Solomon, Scott D; Watkins, Hugh; Heitner, Stephen B; Jacoby, Daniel L; Kupfer, Stuart; Malik, Fady I; Melloni, Chiara; Meng, Lisa; Wei, Jenny; Maron, Martin S; Masri, Ahmad; ,
BACKGROUND:Long-term safety and efficacy data for aficamten in symptomatic obstructive hypertrophic cardiomyopathy are needed. OBJECTIVES/OBJECTIVE:This study aims to evaluate 48-week experience from the ongoing FOREST-HCM (A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten [CK-3773274] in Hypertrophic Cardiomyopathy) study. METHODS:Obstructive hypertrophic cardiomyopathy participants in an aficamten study (REDWOOD-HCM [Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM; NCT04219826]; SEQUOIA-HCM [Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT05186818]) could enroll in this phase 2/3, open-label, extension study. Participants received aficamten 5 mg once daily titrated ≤20 mg based on site-read echocardiographic assessments of Valsalva left ventricular outflow tract gradient and left ventricular ejection fraction. RESULTS:; P = 0.0008), lateral E/e' (-2.2 ± 6.1; P = 0.02), and cardiac biomarkers (P ≤ 0.0031). Aficamten was well tolerated with 2 (4.3%) asymptomatic and transient instances of left ventricular ejection fraction <50% (range: 47%-49%), neither resulting in drug discontinuation, and no new-onset atrial fibrillation. CONCLUSIONS:Aficamten treatment over 48 weeks was well tolerated and associated with substantial and durable relief of obstruction and symptom burden, lower cardiac biomarker levels, and cardiac phenotypic changes, which may indicate favorable cardiac remodeling. (A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten [CK-3773274] in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).
PMID: 40540987
ISSN: 2213-1787
CID: 5871332

Implementing Precision Medicine for Dilated Cardiomyopathy: Insights From the DCM Consortium

Jordan, Elizabeth; Ni, Hanyu; Parker, Patricia; Kinnamon, Daniel D; Owens, Anjali; Lowes, Brian; Shenoy, Chetan; Martin, Cindy M; Judge, Daniel P; Fishbein, Daniel P; Stoller, Douglas; Minami, Elina; Kransdorf, Evan P; Smart, Frank; Haas, Garrie J; Huggins, Gordon S; Ewald, Gregory A; Diamond, Jamie; Wilcox, Jane E; Jimenez, Javier; Wang, Jessica; Tallaj, Jose; Drazner, Mark H; Hofmeyer, Mark; Wheeler, Matthew T; Wever Pinzon, Omar; Shah, Palak; Gottlieb, Stephen S; Katz, Stuart; Shore, Supriya; Tang, W H Wilson; Hershberger, Ray E; ,
PMID: 40528765
ISSN: 2574-8300
CID: 5870922

One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme

Oliva, Angelo; Angiolillo, Dominick J; Valgimigli, Marco; Cao, Davide; Sartori, Samantha; Bangalore, Sripal; Bhatt, Deepak L; Campo, Gianluca; Chehab, Bassem M; Choi, James W; de la Torre Hernandez, Jose M; Feng, Yihan; Ge, Junbo; Gitto, Mauro; Hermiller, James; Krucoff, Mitchell W; Kunadian, Vijay; Makkar, Raj R; Maksoud, Aziz; Neumann, Franz-Josef; Picon, Hector; Saito, Shigeru; Sardella, Gennaro; Thiele, Holger; Toelg, Ralph; Varenne, Olivier; Vogel, Birgit; Vranckx, Pascal; Windecker, Stephan; Mehran, Roxana
BACKGROUND:In patients with diabetes mellitus (DM) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), the optimal duration of dual antiplatelet therapy (DAPT) remains uncertain. AIMS/OBJECTIVE:We sought to compare early DAPT discontinuation in DM and non-DM patients enrolled in the prospective XIENCE Short DAPT programme. METHODS:The effects of 1- versus 3-month DAPT on ischaemic and bleeding outcomes were compared using propensity score stratification. The primary endpoint was a composite of all-cause death or myocardial infarction (MI) at 1 year. The incidence of Bleeding Academic Research Consortium (BARC) Type 2 to 5 bleeding was the key secondary endpoint. RESULTS:Out of 3,352 included patients, 1,299 (38.8%) had DM; diabetic patients had a higher 1-year incidence of death or MI (DM vs non-DM: 10.1% vs 6.6%) and similar BARC 2-5 bleeding (DM vs non-DM: 9.5% vs 9.2%). With 1- versus 3-month DAPT, the incidence of death or MI did not statistically differ in DM patients (adjusted hazard ratio [adjHR] 0.70, 95% confidence interval [CI]: 0.47-1.05) and non-DM patients (adjHR 1.26, 95% CI: 0.87-1.81), although heterogeneity by DM status was evident (p for interaction=0.015). BARC 2-5 bleeding was numerically lower with 1-month DAPT in both groups (DM: adjHR 0.67, 95% CI: 0.45-1.01; non-DM: adjHR 0.78, 95% CI: 0.56-1.07; p for interaction=0.973). CONCLUSIONS:Among HBR patients with DM undergoing PCI, 1-month DAPT, as compared to 3-month DAPT, was not associated with an excess of fatal or non-fatal MI and even reduced the occurrence of bleeding. These findings should be interpreted in the context of a predominantly stable patient population with low procedural complexity and may not be generalisable to higher-risk cases.
PMCID:12151164
PMID: 40522307
ISSN: 1969-6213
CID: 5870762

Impact of Echocardiographic Probability of Pulmonary Hypertension on Prognosis and Outcomes Among Patients With Myeloproliferative Neoplasms

Leiva, Orly; Soo, Steven; Smilowitz, Nathaniel R; Reynolds, Harmony; Shah, Binita; Bernard, Samuel; How, Joan; Lee, Michelle Hyunju; Hobbs, Gabriela
BACKGROUND/UNASSIGNED:Myeloproliferative neoplasms (MPN) are a group of chronic leukemias that are associated with pulmonary hypertension (PH), which has been associated with increased risk adverse outcomes. The echocardiographic characterization of PH in MPN has not been reported, and the prognostic significance of PH among patients with MPN remains unclear. METHODS/UNASSIGNED:Multicenter, retrospective cohort study of patients with MPN with ≥1 echocardiogram from 2010 to 2023. The echocardiographic probability of PH was determined according to the guidelines. The outcomes were hematologic progression and major adverse cardiovascular events. Exploratory analysis included outcomes among patients with right heart catheterization after the first echocardiogram, with PH defined as mean pulmonary artery pressure of >20 mm Hg. Multivariable Fine-Gray competing risk regression was used to estimate the subhazard ratio of hematologic progression and major adverse cardiovascular events. RESULTS/UNASSIGNED:=0.048). CONCLUSIONS/UNASSIGNED:Among patients with MPN, echocardiographic probability of PH was associated with an increased risk of hematologic progression. Prospective studies are needed to assess the optimal use of echocardiography on MPN-specific prognostication.
PMID: 40492300
ISSN: 1942-0080
CID: 5869072

Cardiac Rehabilitation for Patients With Ischemia and No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction With No Obstructive Coronary Arteries (MINOCA): A Review

Hausvater, Anaïs; Reynolds, Harmony R
PURPOSE/OBJECTIVE:Patients with ischemia with no obstructive coronary arteries (INOCA) and myocardial infarction with no obstructive coronary arteries (MINOCA) may benefit from cardiac rehabilitation. Episodes of INOCA can be caused by different mechanisms including coronary microvascular dysfunction and coronary artery spasm, while episodes of MINOCA can be caused by plaque disruption (rupture or erosion), coronary artery spasm, or coronary embolism. Both conditions affect women more than men. REVIEW METHODS/METHODS:The current review evaluates available evidence on exercise and cardiac rehabilitation in patients with INOCA and MINOCA. SUMMARY/CONCLUSIONS:Small studies have shown that exercise training can result in improvements in endothelial function, myocardial perfusion, exercise capacity, and overall wellbeing and quality of life in patients with INOCA. Structured cardiac rehabilitation programs have also been shown to improve symptoms of angina, physical functioning, and quality of life for patients with INOCA. Studies of cardiac rehabilitation among patients with MINOCA have found that only one third participate in cardiac rehabilitation, but among those who do, observational studies and a randomized controlled trial demonstrate a lower risk of major adverse cardiovascular events (such as all-cause mortality and nonfatal myocardial infarction) with cardiac rehabilitation. However, given that INOCA and MINOCA are conditions that predominantly affect women and may be caused by non-atherosclerotic mechanisms, tailoring of traditional cardiac rehabilitation programs (eg, education components) may be desirable to meet the specific needs of these patients. Future studies should explore the effectiveness of tailored cardiac rehabilitation programs with novel delivery methods to optimize programs for patients with INOCA and MINOCA.
PMID: 40476778
ISSN: 1932-751x
CID: 5862802

The double-edged sword of heart rate lowering in cardiovascular disease

Messerli, Franz H; Hofstetter, Louis; Bangalore, Sripal
PMID: 40470720
ISSN: 1522-9645
CID: 5862672